Back to About Us

Hans Schikan, Pharm.D.

Vice Chair of the Board

Prior to co-founding Pharvaris, Mr. Schikan served as Chief Executive Officer of Prosensa Holding N.V., a biopharmaceutical company focusing on novel RNA modulating treatments for rare diseases like Duchenne Muscular Dystrophy, from January 2009 through its IPO on NASDAQ in 2013, until its acquisition by BioMarin Pharmaceutical Inc. in January 2015.

He is currently Chairman of the boards of Microbiotica and Complix, and board member of Vicore Pharma. Mr. Schikan is also a member of the Top Team of the Dutch Top Sector Life Sciences & Health.

Previously, he served on the boards of Sobi, Hansa Biopharma, Asceneuron, Wilson Therapeutics (acquired by Alexion), Therachon (acquired by Pfizer), InteRNA, and VectivBio (acquired by Ironwood Pharmaceuticals). Mr. Schikan has a Pharm.D. degree from Utrecht University.